ADA Advises Against Compounded GLP-1s; Growth Hormone Therapy Guide; T1D Outcomes Up

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and dual GIP/GIP-1 receptor agonists for type 2 diabetes or obesity and instead recommended switching to a different FDA-approved medication if an agent is unavailable. (Diabetes Care)

Patients with hypothyroidism who lost more than over 5 lb with a GLP-1 agent averaged a 0.36 mU/L to 0.55 mU/L reduction in their thyroid-stimulating hormone levels, according to data in Epic Research.

A consensus group of international pediatric endocrinology experts released guidance on the use of long-acting growth hormone therapy in children with growth hormone deficiency. (Journal of Clinical Endocrinology & Metabolism)

In an emulated target trial of nearly 1 million Swedish women ages 50-58, use of oral estrogen-progestin therapy was tied with an increased risk of ischemic heart disease and venous thromboembolism. (The BMJ)

Testosterone levels above minimum threshold concentrations for men didn’t increase sexual desire, a small study found. (Proceedings of the Royal Society B)

Here’s how air pollution may be contributing to osteoporosis risk. (Washington Post)

Canada approved semaglutide (Wegovy) for risk reduction of non-fatal heart attacks in adults with established cardiovascular disease and a BMI of 27 or above, said maker Novo Nordisk.

Transgender people worried about access to treatment under the next Trump administration are stockpiling their medication. (The Guardian)

In an international longitudinal analysis of children with type 1 diabetes (T1D), glycemic outcomes improved and use of diabetes technology increased from 2013 to 2022. (The Lancet Diabetes & Endocrinology)

Please enable JavaScript to view the comments powered by Disqus.